On Oct. 22, Roche reported 7% growth at constant exchange rates (8% pharma, 5% diagnostics) in the third quarter, and management maintained full-year guidance for mid-single-digit sales and high-single-digit core EPS growth, also at constant rates. Shares traded flat.
Roche and its innovative US arm Genentech have a solid history of generating blockbuster therapies in oncology, and Roche's pipeline is full of novel candidates, with a particularly large late-stage pipeline.
Roche's immuno-oncology drug Tecentriq was launched third to market behind Bristol's Opdivo and Merck's Keytruda, raising questions about Roche's innovation.
Metric | ROP | REGN | ABBV |
|---|---|---|---|
Price/Earnings (Normalized) | 21.24 | 17.79 | 33.02 |
Price/Book Value | 9.51 | 2.79 | — |
Price/Sales | 4.99 | 5.71 | 7.82 |
Price/Cash Flow | 15.63 | 16.51 | 21.97 |
Metric | ROP | REGN | ABBV |
|---|---|---|---|
Quick Ratio | 0.80 | 2.72 | 0.56 |
Current Ratio | 1.23 | 3.35 | 0.87 |
Interest Coverage | 13.49 | 106.89 | 5.20 |
Metric | ROP | REGN | ABBV |
|---|---|---|---|
Return on Assets (Normalized) | 15.81% | 14.40% | 16.61% |
Return on Equity (Normalized) | 48.77% | 18.83% | — |
Return on Invested Capital (Normalized) | 23.90% | 15.64% | 36.97% |
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Eli Lilly and Co LLY | LOCK|c!Lm?dGt | LOCK|%> | $1T | |||
| Johnson & Johnson JNJ | LOCK|#^VBDJ | LOCK|?@k | $665B | |||
| AbbVie Inc ABBV | LOCK|<&#TXN | LOCK|>K | $515B | |||
| Roche Holding AG ADR RHHBY | LOCK|%!nkl@Cr | LOCK|rD | $383B | |||
| Merck & Co Inc MRK | LOCK|?>%SS< | LOCK|@ZZ | $362B | |||
| Novartis AG ADR NVS | LOCK|H^$Q?l#$ | LOCK|<!& | $308B | |||
| AstraZeneca PLC AZN | LOCK|WZSpWfGv | LOCK|P^ | $291B | |||
| Amgen Inc AMGN | LOCK|g@?Z@gL& | LOCK|#x | $249B | |||
| Gilead Sciences Inc GILD | LOCK|rbdqZ! | LOCK|pH | $207B | |||
| Novo Nordisk AS ADR NVO | LOCK|nx@Y?c | LOCK|@Z! | $178B |
United States